Cognito Therapeutics’ investigational therapy, Spectris AD™, represents a breakthrough in the treatment of Alzheimer’s disease through non-invasive neuromodulation. Unlike traditional drug-based approaches, Spectris AD™ uses synchronized light and sound stimulation at a 40Hz gamma frequency to restore natural brain rhythms disrupted by Alzheimer’s, aiming to address the disease at its root through physics-based intervention. This novel technology is designed for daily, at-home use, making it both accessible and scalable for widespread patient adoption, while also receiving FDA Breakthrough Device Designation for its potential impact.

The recently published post hoc analysis of the OVERTURE feasibility clinical trial reinforces the therapy’s promise. In a six-month randomized phase followed by a 12-month open-label extension, Spectris AD™ demonstrated significant delays in disease progression—extending the time patients could maintain cognitive function, daily activity performance, and brain volume. Compared to sham treatment, participants experienced up to 10 months of preserved function, underscoring the therapy’s ability to meaningfully delay decline and enhance quality of life for patients and caregivers.